Pharming announces FDA acceptance of sNDA for lower Joenja doses
PHAR•The FDA accepted Pharming’s supplemental application for lower Joenja doses to treat children with APDS and granted it priority review. The target action date is January 30, 2027.
1. Priority review granted
Pharming said the FDA accepted its supplemental new drug application for lower doses of Joenja to treat children with APDS and granted the application priority review. The target action date is January 30, 2027.
